Comprehensive analysis identifies PRAME as a key marker for distinguishing atypical fibroxanthoma from malignant melanoma, aiding diagnosis.
A comprehensive immunohistochemical panel is essential for the accurate diagnosis of AFX. The absence of PRAME expression, together with block-type CD10 positivity, supports the distinction of AFX from malignant melanoma and other histological mimics, facilitating appropriate clinical management.
No takes yet. Share an insight, caveat, or question.
Sahin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: